Low-Dose THC Plus an Anti-Inflammatory Drug Shows Promise for Alzheimer's Prevention | Research

The takeaway

Combining low-dose THC with celecoxib (a COX-2 inhibitor) reduced both amyloid and tau pathology in Alzheimer's mice and improved cognitive function more than either drug alone.

Alzheimer's researchers, neurologists, families affected by dementia, and drug development professionals interested in repurposing existing medications.

What the researchers found

THC (3.0 mg/kg) alone or with celecoxib (1.0 mg/kg) reduced amyloid-beta and tau pathology, enhanced synaptic markers, and prevented cognitive decline. The combination produced greater improvements in spatial learning and mitigated THC-induced neuroinflammation. Both drugs are already FDA-approved.

Why it matters

Both THC (as dronabinol/nabilone) and celecoxib are already FDA-approved, meaning this combination could potentially advance to clinical trials rapidly if preclinical results hold up — a rare advantage in Alzheimer's drug development.

The numbers in context

THC 3.0 mg/kg + celecoxib 1.0 mg/kg. Reduced Aβ and tau pathologies. Enhanced synaptic marker expression. Combination improved spatial learning more than THC alone. Gene expression changes reversed AD-associated patterns.

How the study worked

Preclinical study treating Alzheimer's model mice with low-dose THC alone or combined with celecoxib, measuring amyloid/tau pathology, synaptic markers, cognitive function, neuroinflammation, and gene expression changes.

What this study cannot tell us

Mouse model doesn't fully replicate human AD. THC dose translation to humans is uncertain. Long-term safety of the combination is unknown. Single AD model tested.

How to read the evidence

Comprehensive preclinical study with gene expression and behavioral endpoints. The use of already-approved drugs strengthens translational relevance.

When this study was published

Recent study proposing a novel combination strategy using existing FDA-approved medications for Alzheimer's prevention.

The bigger picture

Alzheimer's treatment has seen decades of failures. The strategy of combining an existing cannabinoid with an anti-inflammatory to counter THC's own inflammatory effects while leveraging its neuroprotective properties is an elegant repurposing approach.

Questions still open

Could this combination prevent AD onset in high-risk individuals? Would the combination's cognitive benefits translate to human patients with existing dementia?

Common questions

Could THC treat Alzheimer's disease?

Low-dose THC showed benefits in this mouse study, but combining it with celecoxib was even better — the anti-inflammatory countered THC's own inflammatory effects while both drugs attacked Alzheimer's pathology from different angles.

Why combine THC with an anti-inflammatory?

THC has neuroprotective effects but also induces some neuroinflammation via COX-2. Adding celecoxib (a COX-2 inhibitor) blocks the unwanted inflammation while preserving THC's benefits, creating a net positive effect.

Read the original research

A Combination of Low-Dose Δ9-THC and Celecoxib as a Therapeutic Strategy for Alzheimer's Disease.

Aging and disease

View on PubMed ↗Publisher’s paper ↗

Citation

Zhang, Jian; Zhu, Dexiao; Hu, Mei; Pan, Mingzhe; Chen, Chu. (2025). A Combination of Low-Dose Δ9-THC and Celecoxib as a Therapeutic Strategy for Alzheimer's Disease.. Aging and disease. https://doi.org/10.14336/AD.2025.1206